Medexus Pharmaceuticals Inc. (TSE:MDP) Receives C$4.57 Consensus PT from Brokerages

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been given an average recommendation of “Buy” by the seven research firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and four have issued a strong buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is C$4.57.

Separately, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 11th.

Medexus Pharmaceuticals Stock Performance

TSE:MDP opened at C$2.80 on Thursday. The stock has a 50-day simple moving average of C$2.89 and a two-hundred day simple moving average of C$2.80. Medexus Pharmaceuticals has a 52-week low of C$1.71 and a 52-week high of C$5.56. The firm has a market capitalization of C$90.32 million, a PE ratio of 140.00 and a beta of 1.60.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.